CD274 and cancer: Currently, PD-1/PD-L1-targeting treatments have significantly affected cancer treatment approaches, and PD-L1 expression has emerged as an indicator for the selection of patients who are more likely to benefit from PD-1/PD-L1 inhibitors (4, 5).